ARTICLE | Top Story
SEPR, JNJ suspend ticalopride trials
April 23, 2001 7:00 AM UTC
Sepracor (SEPR) partner Janssen (Beerse, Belgium), a subsidiary of Johnson & Johnson (JNJ), suspended two Phase II studies of ticalopride (+)-norcisapride in patients with gastroesophageal reflux dise...